Merck & Co Inc
MRK
Market Cap$196.28B
Close$
Earnings Call Q4 2024
February 4, 2025 - AI Summary
Strong Fourth Quarter Results: Merck reported total revenues of $15.6 billion for Q4 2024, reflecting a 7% increase year-over-year (9% excluding foreign exchange impact). The Human Health business saw an 8% sales growth, driven mainly by oncology products, including $7.8 billion from KEYTRUDA (up 21%).
Challenges with GARDASIL in China: GARDASIL sales decreased by 18% to $1.6 billion, primarily due to low demand in China, exacerbated by elevated inventory levels. Merck plans to temporarily pause shipments to China to help reduce inventory, which is a significant negative factor affecting revenue forecasts for 2025.
Outlook and Revenue Guidance for 2025: Merck expects total revenue for 2025 to be between $64.1 and $65.6 billion, indicating growth of 2% to 4% (excluding the negative impact from foreign exchange and GARDASIL sales in China). Excluding GARDASIL’s impact, overall growth could be between 7% and 9%.
Exclusive for Stockcircle Pro members
Sign up
$224.90
184.8% upside
Current Fair Value
184.8% upsideUndervalued by 184.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $196.28 Billion |
|---|---|
| Enterprise Value | $196.28 Billion |
| Dividend Yield | $3.16 (4.05128205128205%) |
| Earnings per Share | $6.74 |
| Beta | 0.42 |
| Outstanding Shares | 2,541,000,106 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 11.58 |
|---|---|
| PEG | -2.86 |
| Price to Sales | 3.16 |
| Price to Book Ratio | 4.65 |
| Enterprise Value to Revenue | 3.06 |
| Enterprise Value to EBIT | 8.26 |
| Enterprise Value to Net Income | 11 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Merck & Co Inc
CEO: Kenneth Frazier